Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Fact: multiple myeloma therapies are based on clinical trials. Fact: clinical trials are based on patients of European descent.
The challenge that multiple myeloma patients face when confronting their diagnosis of cancer is that conventional oncology considers MM to be incurable. Many oncologists tell patients that while MM is incurable it is very treatable. In the case of this incurable cancer, very treatable means that conventional oncology can put you into remission.
The challenge faced by African American myeloma patients is summerized in the study below. While a caucasian myeloma patient can feel pretty good about his/her chances of reaching remission, African American myeloma patients cannot.
The FDA bases approvals of chemotherapy regimens on clinical trials. Conventional oncologists rely on the FDA to tell them what chemotherapy regimens to use on myeloma patients. According to the article below, the clinical trial evidence for myeloma is based largely on caucasian (white) myeloma patients. Black myeloma patients, according to the study below, have different genetics than white myeloma patients. Black people are three times more likely to be diagnosed with multiple myeloma than white people are.
I am both a MM survivor and MM cancer coach. Several years of aggressive MM therapies didn’t do much for me other than give me a host of short, long-term and late stage side effects. I have remained in complete remission from my MM since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, etc. therapies.
To learn more about evidence-based, non-toxic therapies and how to develop an anti-Multiple Myeloma lifestyle, please watch the brief video below:
“Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study led by researchers at the Keck School of Medicine of USC…
That trend is problematic considering that African-Americans — the most at-risk population for multiple myeloma — have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective…
The study was published on Nov. 22 in PLOS Genetics. Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African-Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4…
“There are clearly molecular differences between African-American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients…”
African-Americans are two times more likely than white people to die from multiple myeloma, the study stated…
“African-American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy-to-treat cancer.